Retatrutide 6 mg vial GLP3 (Triple G)

What is Retatrutide 6 mg

Retatrutide 6 mg is an experimental peptide (an agonist of three receptors: GLP-1, GIP and the glucagon receptor) developed by Eli Lilly and Company for the treatment of obesity and type 2 diabetes. Retatrutide is designed to comprehensively affect processes related to weight control, blood sugar levels and energy metabolism in the body. In practice, this means that Retatrutide simultaneously reduces appetite, slows gastric emptying, improves insulin sensitivity i increases the rate of energy burning.

How Retatrutide 6 mg works - the scientific take

Retarutide 6 mg acts on three key receptors:

• GLP-1 (glucagon-like peptide-1) receptor - increases insulin release, decreases glucagon secretion, slows gastric emptying and reduces appetite. 
• GIP receptor (glucose-dependent insulinotropic peptide) - further supports metabolic effects, stimulates insulin action and reduces fat storage. 
• Glucagon receptor (GCGR) - activation results in increased energy burning (thermogenesis) and can lead to greater energy expenditure. 
  Through this combination of mechanisms, Retatrutide reduces caloric intake (less cravings, slower gastric emptying) and increases energy consumption and improves metabolic indicators (e.g. insulin resistance). 

Effects according to clinical trials on Retatrutide 6 mg

Clinical trials are showing promising results:

• W research Phase 2 trial, in adults with obesity, after 48 weeks of treatment with the highest dose of Retatrutide, an average weight loss of about -24.2%. 

• Improved metabolic parameters: reduced waist circumference, improved insulin resistance (HOMA-IR), reduced liver fat.

• Compared to placebo, the effects were statistically significant.
  However, it is worth noting that the study is still ongoing, and the safety profile and long-term effects are not yet fully established.

Retatrutide 6mg dosage schedule - according to available sources

Based on available research:

• Subcutaneous administration once a week. 
• Doses tested in the study included 1 mg, 4 mg, 8 mg, 12 mg per week - the highest doses produced the greatest weight effects. 
• Since the drug is not yet approved, dosage outside of clinical trials is not established and each case should be evaluated by an appropriate specialist.

Comparison of Retatrutide with other peptides with a similar profile

It is worth contrasting Retatrutide 6 mg with other peptide drugs used or being studied for the treatment of obesity:

• Tirzepatide - a drug that acts as a GIP and GLP-1 agonist, achieved a weight reduction of ~15-20% after about 72 weeks in phase 3 studies.

• Standard GLP-1 agonists (e.g. Semaglutide) - Often weight reduction reaches ~10-15% depending on the dose and duration of therapy.

In this context, Retatrutide seems to offer a greater efficiency (reductions >20%) than with Semaglutide (~10-15%) or Tirzepatide (~15-20%). Thanks to its triple mechanism of action, Retatrutide not only reduces appetite, but also increases energy burning i improves fat metabolism, among other things, reducing liver fat and waist circumference.

Retatrutida - summary

Retatrutida 6mg is an innovative peptide drug in clinical trials that has the potential to revolutionize the treatment of obesity and type 2 diabetes with its triple mechanism of action (GLP-1, GIP, glucagon). Studies to date show very significant weight loss (often more than 20 %) and improvements in metabolic parameters. Nevertheless - since the drug is still in the research phase - further long-term conclusions on safety, optimal dosing and real-world efficacy in clinical populations are needed

Source:

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.